ISOLATION AND BEHAVIOR OF SPIRO[2,5]OCTA-1,4-DIENE-3-ONE

Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions

Drug conjugates are obtained from tumor-located vectors connected to cytotoxic agents via linkers, which are designed to deliver hyper-toxic payloads directly to targeted cancer cells. These drug conjugates include antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), small molecule-drug conjugates (SMDCs), nucleic acid aptamer-drug conjugates (ApDCs), and virus-like drug conjugate (VDCs), which show great therapeutic value in the clinic. Drug conjugates consist of a targeting carrier, a linker, and a payload. Payloads are key therapy components. Cytotoxic molecules and their derivatives derived from natural products are commonly used in the payload portion of conjugates. The ideal payload should have sufficient toxicity, stability, coupling sites, and the ability to be released under specific conditions to kill tumor cells. Microtubule protein inhibitors, DNA damage agents, and RNA inhibitors are common cytotoxic molecules. Among these conjugates, cytotoxic molecules of natural origin are summarized based on their mechanism of action, conformational relationships, and the discovery of new derivatives. This paper also mentions some cytotoxic molecules that have the potential to be payloads. It also summarizes the latest technologies and novel conjugates developed in recent years to overcome the shortcomings of ADCs, PDCs, SMDCs, ApDCs, and VDCs. In addition, this paper summarizes the clinical trials conducted on conjugates of these cytotoxic molecules over the last five years. It provides a reference for designing and developing safer and more efficient conjugates.

Diastereoselective synthesis of spiro-cyclopropanyl-cyclohexadienones via direct sulfide-catalyzed [2 + 1] annulation of para-quinone methides with bromides

A sulfide-catalyzed [2 + 1] annulation of para-quinone methides with diverse bromides was disclosed to access appealing spiro-cyclopropanyl-cyclohexadienones with high diastereoselectivity.

Formation and Mechanism for Reactions of Ring-Substituted Phenonium Ions in Aqueous Solution

The results of studies on the structure and reactivity of spiro[5.2]oct-5,7-diene-4yl carbocation [phenonium ion] have had a significant impact on the course of discussion about the distinction between classical and nonclassical carbocations. This minireview will present a brief overview of the structure, bonding and reactivity of ring substituted phenonium ions (X-4+), with an emphasis on work completed since 2004. The discussion will focus on the development of new experimental protocol for determination of the selectivity for addition of nucleophilic anions to X-4+ in aqueous solution. The existing relationships between carbocation lifetime and nucleophilic selectivity, and the known lifetime of ca 140 sec for spiro[2.5]oct-4,7-diene-6-one provide rough estimates of the lifetimes for 4-Me-X-4+ and 4-MeO-X-4+ in aqueous solution. Evidence is presented that nucleophile addition to X-4+ proceeds through an "exploded" transition state, with relatively weak bonding the nucleophile and leaving group, and the development of significant positive charge at the reacting primary cyclopropyl carbon.

Antibody-drug conjugates: an emerging concept in cancer therapy

Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient. Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach. However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own. Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compound selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents. The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field. This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technology, i.e., the antibody, the cytotoxic compound, and the linker connecting them, leading to the current successes. The design of ADCs currently in clinical development, and results from mechanistic studies and preclinical and clinical evaluation are discussed. Emerging technologies that seek to further advance this exciting area of research are also discussed.

Substituent Effects on the Formation and Nucleophile Selectivity of Ring-Substituted Phenonium Ions in Aqueous Solution

The reaction of 2-(4-methyphenyl)ethyl tosylate (Me-1-OTs) in 50/50 (v/v) trifluoroethanol/water at 25 °C is first-order in the concentration of azide anion nucleophile. A carbon-13 NMR analysis of the products of the reactions of Me-1-[α-¹³C]OTs in 50/50 (v/v) trifluoroethanol/water at 25 °C shows the formation of Me-1-[β-¹³C]OH, Me-1-[β-¹³C]OCH₂CF₃ and Me-1-[β-¹³C]N₃ from the trapping of a symmetrical 4-methylphenonium ion reaction intermediate Me-2⁺. The formation of Me-1-[α-¹³C]N₃ by concerted bimolecular displacement of azide ion at Me-1-[α-¹³C]OTs (k_N = 3.8 × 10^-6 M^-1 s^-1) and of Me-1-[α-¹³C]OH and Me-1-[α-¹³C]OCH₂CF₃ by concerted bimolecular displacement of solvent (k_solv = 1.8 × 10^-8 s^-1) is also observed. An analysis of the rate and product data provides a value of k_az/k_s = 32 M^-1 for partitioning of Me-2⁺ between addition of azide ion and solvent that is nearly 3-fold smaller than k_az/k_s = 83 M^-1 reported in an earlier study on the partitioning of MeO-2⁺ [J. Org. Chem.2011, 76, 9568]. This change is attributed to a decrease in nucleophile selectivity with increasing electrophile reactivity for the activation-limited addition of solvent and azide anion to X-2⁺. These data set a limit of 1/k_s ≥ 10^-7 s for the lifetime of Me-2⁺ in aqueous solution.

Formation and stability of the 4-methoxyphenonium ion in aqueous solution

The reaction of 2-methoxyphenylethyl tosylate (MeO-1-Ts) is first-order in [N(3)(-)]. A carbon-13 NMR analysis of the products of the reactions of MeO-1-[α-(13)C]Ts shows the formation of MeO-1-[β-(13)C]OH and MeO-1-[β-(13)C]N(3) from the trapping of a symmetrical 4-methoxyphenonium ion reaction intermediate 2(+). An analysis of the rate and product data provides a value of k(az)/k(s) = 83 M(-1) for partitioning of 2(+) between addition of azide ion and solvent. These data set a limit for the lifetime of 2(+) in aqueous solution.

Synthesis and characterization of a cyclobutane duocarmycin derivative incorporating the 1,2,10,11-tetrahydro-9H-cyclobuta[c]benzo[e]indol-4-one (CbBI) alkylation subunit

The synthesis of 1,2,10,11-tetrahydro-9H-cyclobuta[c]benzo[e]indol-4-one (17, CbBI), which contains a deep-seated fundamental structural modification in the CC-1065 and duocarmycin alkylation subunit consisting of the incorporation of a ring-expanded fused cyclobutane (vs cyclopropane), its chemical and structural characterization, and its incorporation into a key analogue of the natural products are detailed. The approach to the preparation of CbBI was based on a precedented (Ar-3' and Ar-5') but previously unknown Ar-4' spirocyclization of a phenol onto a tethered alkyl halide to form the desired cyclobutane. The conditions required for the implementation of the Ar-4' spirocyclization indicate that the entropy of activation substantially impacts the rate of reaction relative to that for the much more facile Ar-3' spirocyclization, while the higher enthalpy of activation slows the reaction relative to an Ar-5' spirocyclization. The characterization of the CbBI-based agents revealed their exceptional stability and exquisite reaction regioselectivity, and a single-crystal X-ray structure analysis of N-Boc-CbBI (13) revealed their structural origins. The reaction regioselectivity may be attributed to the stereoelectronic alignment of the two available cyclobutane bonds with the cyclohexadienone π-system, which resides in the bond that extends to the less substituted cyclobutane carbon for 13. The remarkable stability of N-Boc-CbBI (which is stable even at pH 1) relative to N-Boc-CBI containing a cyclopropane (t(1/2) = 133 h at pH 3) may be attributed to a combination of the increased extent of vinylogous amide conjugation, the nonoptimal geometric alignment of the cyclobutane with the activating cyclohexadienone, and the intrinsic but modestly lower strain energy (1.8 kcal/mol) of a cyclobutane versus a cyclopropane.